Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Rowe

Showing results (451-460 of 504) with videos related to

Pageof 51
Sort By:
Molecular Imaging and Biology|April 16, 2016
PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate CancerSteven P Rowe, Katarzyna J Macura, Esther Mena, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 15, 2021
First-in-human neuroimaging of soluble epoxide hydrolase using [<sup>18</sup>F]FNDP PETJennifer M Coughlin, Stephanie Slania, Yong Du, et al.
EJNMMI Research|December 29, 2022
Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PETKevin H Leung, Steven P Rowe, Jeffrey P Leal, et al.
Molecular Imaging and Biology|April 22, 2015
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate CancerZsolt Szabo, Esther Mena, Steven P Rowe, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 8, 2026
PET-based risk stratification for adverse events under [<sup>225</sup>Ac]Ac-PSMA radioligand therapyLiam Widjaja, Sophie C Siegmund, Franz J Gildehaus, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 4, 2025
Phase 1 Study of [<sup>177</sup>Lu]Lu-NeoB in Patients with Advanced Solid Tumors Overexpressing Gastrin-Releasing Peptide Receptor: Preliminary Safety and Dosimetry ResultsErik S Mittra, Lilja B Solnes, Astrid A M van der Veldt, et al.
Cancers|May 14, 2025
Inhibition of Mitochondrial-Associated Protein MAGMAS Resensitizes Chemoresistant Prostate Cancer Cells to DocetaxelAlfonso M Durán, Kristen Whitley, Krystal Santiago, et al.
Annals of Nuclear Medicine|August 24, 2017
Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted <sup>18</sup>F-DCFPyL in peripheral gangliaRudolf A Werner, Sara Sheikhbahaei, Krystyna M Jones, et al.
Nuclear Medicine Communications|January 29, 2025
Lack of effect of renal function on uptake of 99m Tc-sestamibi in renal massesAlireza Amindarolzarbi, Kendall Satcowitz, Adham Khalil, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 19, 2024
Initial Experience with [<sup>177</sup>Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome PredictionAndrei Gafita, Andrew Voter, Somya Shesadri, et al.
Pageof 51

Showing results (451-460 of 504) with videos related to

Sort By:
Pageof 51
Molecular Imaging and Biology|April 16, 2016
PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate CancerSteven P Rowe, Katarzyna J Macura, Esther Mena, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 15, 2021
First-in-human neuroimaging of soluble epoxide hydrolase using [<sup>18</sup>F]FNDP PETJennifer M Coughlin, Stephanie Slania, Yong Du, et al.
EJNMMI Research|December 29, 2022
Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PETKevin H Leung, Steven P Rowe, Jeffrey P Leal, et al.
Molecular Imaging and Biology|April 22, 2015
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate CancerZsolt Szabo, Esther Mena, Steven P Rowe, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 8, 2026
PET-based risk stratification for adverse events under [<sup>225</sup>Ac]Ac-PSMA radioligand therapyLiam Widjaja, Sophie C Siegmund, Franz J Gildehaus, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 4, 2025
Phase 1 Study of [<sup>177</sup>Lu]Lu-NeoB in Patients with Advanced Solid Tumors Overexpressing Gastrin-Releasing Peptide Receptor: Preliminary Safety and Dosimetry ResultsErik S Mittra, Lilja B Solnes, Astrid A M van der Veldt, et al.
Cancers|May 14, 2025
Inhibition of Mitochondrial-Associated Protein MAGMAS Resensitizes Chemoresistant Prostate Cancer Cells to DocetaxelAlfonso M Durán, Kristen Whitley, Krystal Santiago, et al.
Annals of Nuclear Medicine|August 24, 2017
Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted <sup>18</sup>F-DCFPyL in peripheral gangliaRudolf A Werner, Sara Sheikhbahaei, Krystyna M Jones, et al.
Nuclear Medicine Communications|January 29, 2025
Lack of effect of renal function on uptake of 99m Tc-sestamibi in renal massesAlireza Amindarolzarbi, Kendall Satcowitz, Adham Khalil, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 19, 2024
Initial Experience with [<sup>177</sup>Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome PredictionAndrei Gafita, Andrew Voter, Somya Shesadri, et al.
Pageof 51